1,411 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Top Research Reports for Novartis, AbbVie & Sanofi http://www.zacks.com/research-daily/665423/top-research-reports-for-novartis-abbvie-sanofi?cid=CS-ZC-FT-research_daily-665423 Dec 11, 2019 - Top Research Reports for Novartis, AbbVie & Sanofi
Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA http://www.zacks.com/stock/news/665392/roches-rhhby-sbla-for-asthma-drug-xolair-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-665392 Dec 11, 2019 - The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.
Why Biotech ETFs are Surging to New Highs http://www.zacks.com/stock/news/664321/why-biotech-etfs-are-surging-to-new-highs?cid=CS-ZC-FT-etf_news_and_commentary-664321 Dec 10, 2019 - increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research http://www.zacks.com/stock/news/663717/sanofi-unveils-growth-strategy-ends-diabetes-cv-research?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-663717 Dec 10, 2019 - Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Gilead (GILD) Announces Positive Long-Term Data on Yescarta http://www.zacks.com/stock/news/662055/gilead-gild-announces-positive-long-term-data-on-yescarta?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-662055 Dec 09, 2019 - Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.
Biogen Up on New Data on Alzheimer's Candidate Aducanumab http://www.zacks.com/stock/news/657638/biogen-up-on-new-data-on-alzheimers-candidate-aducanumab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657638 Dec 06, 2019 - Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Regeneron Reports Positive Data on Rare Blood Disorder Drug http://www.zacks.com/stock/news/657613/regeneron-reports-positive-data-on-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657613 Dec 06, 2019 - Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen https://www.fool.com/investing/2019/12/02/why-novartis-97-billion-purchase-of-the-medicines.aspx?source=iedfolrf0000001 Dec 02, 2019 - Novartis's purchase comes with investigational cardiovascular drug inclisiran, a competitor with potential to dethrone Amgen's already embattled Repatha.
5 New Drug Approvals the FDA Gave Top Priority https://www.fool.com/investing/2019/11/29/5-new-drug-approvals-the-fda-gave-top-priority.aspx?source=iedfolrf0000001 Nov 29, 2019 - Here's why the FDA recently approved five new drugs way ahead of schedule.
Euronav NV Frontline IMO 2020 Strategies: Assessing Which Will Be Superior https://seekingalpha.com/article/4309663-euronav-nv-frontline-imo-2020-strategies-assessing-will-superior?source=feed_all_articles Nov 28, 2019 - IMO 2020 sulfur regulation goes into effect January 1, 2020.Frontline has chosen a scrubber strategy.Euronav has chosen a pre-purchase at bulk prices and store compliant fuel.The most economical strat

Pages: 123456789...142

<<<Page 4>